Seeing Is Believing

Currently out of the existing stock ratings of Roy Buchanan, 101 are a BUY (97.12%), 3 are a HOLD (2.88%).
Analyst Roy Buchanan, currently employed at JMP, carries an average stock price target met ratio of 32.58% that have a potential upside of 49.58% achieved within 121 days.
Roy Buchanan’s has documented 186 price targets and ratings displayed on 15 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CDTX, Cidara Therapeutics at 21-Oct-2025.
Analyst best performing recommendations are on CDTX (CIDARA THERAPEUTICS).
The best stock recommendation documented was for CDTX (CIDARA THERAPEUTICS) at 6/2/2025. The price target of $47 was fulfilled within 23 days with a profit of $24.33 (107.32%) receiving and performance score of 46.66.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 19-Jan-2023
$5.5
$0.84 (18.03%)
1 years 3 months 7 days ago
(26-Jun-2025)
1/2 (50%)
$0.1 (1.85%)
13
Buy Since 13-Jun-2025
$5
$0.34 (7.30%)
1 years 3 months 20 days ago
(13-Jun-2025)
1/1 (100%)
$-0.57 (-10.23%)
185
Buy Since 19-Jan-2022
$10
$5.34 (114.59%)
$16
1 years 4 months 5 days ago
(28-May-2025)
0/8 (0%)
$5.56 (125.23%)
Hold Since 22-Oct-2021
$3.9
$-0.76 (-16.31%)
$35
2 years 1 months 1 days ago
(02-Sep-2024)
2/2 (100%)
$0.76 (24.20%)
97
Sell Since 21-Aug-2023
$8
$3.34 (71.67%)
$20
3 years 1 months 12 days ago
(21-Aug-2023)
4/4 (100%)
$-0.89 (-10.01%)
32
What Year was the first public recommendation made by Roy Buchanan?